Aetna Commercial Alert: National Precertification List Changes — What Providers Need to Know

Aetna’s July 2026 provider update includes meaningful changes to its National Precertification List (NPL) — the list of services and drugs requiring prior authorization before Aetna will pay. These changes apply to commercial Aetna plans, and practices billing Aetna commercial insurance across any specialty need to be aware of what is changing and when.

The update covers three key areas: NPL drug additions effective July 1 and October 1, 2026; upcoming changes to maternity care coding; and a reminder about the physiological monitoring policy and place of service requirements.

Part 1: Changes to the National Precertification List (NPL) — Drug Additions

Effective July 1, 2026

Aetna is adding several drugs to its National Precertification List — meaning these medications now require prior authorization before Aetna will approve coverage. Practices prescribing or administering any of the following must obtain PA through Aetna before the service date:

Key additions relevant to specialty practices:

Faricimab (Vabysmo) — J3398 This anti-VEGF agent for diabetic macular edema and neovascular AMD is now on the Aetna NPL effective July 1, 2026. Ophthalmology and retina practices currently administering Vabysmo to Aetna commercial members without PA must add Aetna PA to their pre-injection workflow immediately. This change applies to commercial Aetna — note that Aetna Better Health (Medicaid) has separate PA requirements.

GLP-1 / Weight Loss Injectable Agents Aetna is adding GLP-1 receptor agonist injectables — including agents used for weight management — to the NPL for commercial plans. Endocrinology, internal medicine, and obesity medicine practices prescribing semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) for Aetna commercial patients must verify current PA status and initiate PA requests through Aetna’s portal before prescribing.

Oncology and Specialty Biologics Multiple oncology drugs and specialty biologics are included in the July 1 additions. Oncology practices and infusion centers should download the full updated NPL from the Aetna provider portal and cross-reference against their formulary.

Effective October 1, 2026

Additional drugs take effect October 1. Specialty practices — particularly rheumatology, dermatology, gastroenterology, and neurology — should review the full October 1 list on the Aetna provider portal as it contains specialty biologic agents relevant to those practices.

⚠️ Payer adoption timeline: Even after NPL effective dates, Aetna’s claims editing systems may take 60–90 days to fully enforce the new PA requirements. Do not assume you can continue without PA during the transition window — submit PA requests for all newly listed drugs starting on the effective date.

Part 2: Upcoming Changes to Maternity Care Coding

Aetna’s update includes revised guidance on maternity care coding for commercial members — specifically addressing the antepartum, delivery, and postpartum global obstetric package billing.

Key points from the maternity update:

Aetna is aligning coding expectations with current Medicare and industry standards for the OB global package
Antepartum care components must be coded with specificity reflecting the number of visits provided — the global OB package CPT codes (59400, 59510, 59610, 59618) should reflect complete packages only when all components are delivered
Documentation supporting the antepartum visit count is increasingly scrutinized — ensure OB notes clearly reflect each antepartum encounter

OB/GYN and maternal-fetal medicine practices billing Aetna commercial for obstetric care should review their maternity coding templates against Aetna’s updated guidance and confirm documentation practices align with the new expectations.

Part 3: Physiological Monitoring (RPMS) — Place of Service Reminder

Aetna’s update reinforces its policy on Remote Physiological Monitoring Services (RPMS) — specifically the requirement that the therapeutic use location must match the Place of Service (POS) submitted on the claim.

Key requirement:

RPMS claims must reflect the POS where the patient receives therapeutic use of the device, not the billing provider’s office location
For patients using RPMS devices at home, POS 12 (Patient’s Home) should be reflected appropriately in the claim structure
Mismatched POS for RPMS claims is a growing denial trigger as Aetna’s claim editing systems apply this validation more consistently

Practices billing RPMS codes for Aetna commercial patients should audit recent RPMS claims for POS accuracy and update billing templates to capture the correct therapeutic use location.

What Your Practice Should Do Right Now

For NPL drug additions (July 1, 2026 — effective now):

Download the updated Aetna NPL from the Aetna provider portal at provider.aetna.com
Flag every drug on the July 1 and October 1 addition lists that your practice prescribes or administers
For each newly listed drug — initiate Aetna PA workflow immediately for any Aetna commercial patient scheduled to receive that drug after July 1
For Vabysmo (J3398) specifically — ophthalmology and retina practices need PA in place before any Aetna commercial injection appointment scheduled after July 1
For GLP-1 agents — confirm PA status for every Aetna commercial patient currently on or being started on these medications

For maternity coding:

OB/GYN practices should review antepartum visit documentation against the updated Aetna guidance
Confirm OB global package codes reflect complete packages only when all components are delivered

For RPMS:

Audit RPMS claims for POS accuracy
Update RPMS billing templates to capture correct therapeutic use location (POS 12 for home)

More Information

For the complete NPL list and additional details on all three policy updates, log in to your Aetna provider portal at provider.aetna.com or contact your Aetna Provider Relations representative directly.